A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Public ClinicalTrials.gov record NCT07182149. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Study identification
- NCT ID
- NCT07182149
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 29, 2025
- Primary completion
- May 29, 2027
- Completion
- Oct 30, 2028
- Last update posted
- Aug 17, 2026
2025 – 2028
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Normunity Investigational Site | Denver | Colorado | 80220 | Recruiting |
| Normunity Investigational Site | New Haven | Connecticut | 06519 | Recruiting |
| Normunity Investigational Site | Washington D.C. | District of Columbia | 20007 | Recruiting |
| Normunity Investigational Site | Boston | Massachusetts | 02114 | Recruiting |
| Normunity Investigational Site | Boston | Massachusetts | 02215 | Recruiting |
| Normunity Investigational Site | Minneapolis | Minnesota | 55425 | Recruiting |
| Normunity Investigational Site | St Louis | Missouri | 63108 | Recruiting |
| Normunity Investigational Site | Hackensack | New Jersey | 07601 | Recruiting |
| Normunity Investigational Site | Maumee | Ohio | 43537 | Recruiting |
| Normunity Investigational Site | Oklahoma City | Oklahoma | 73104 | Recruiting |
| Normunity Investigational Site | Philadelphia | Pennsylvania | 19107 | Recruiting |
| Normunity Investigational Site | Philadelphia | Pennsylvania | 19111 | Recruiting |
| Normunity Investigational Site | Charleston | South Carolina | 29425 | Recruiting |
| Normunity Investigational Site | Nashville | Tennessee | 37203 | Recruiting |
| Normunity Investigational Site | Dallas | Texas | 75230 | Recruiting |
| Normunity Investigational Site | Houston | Texas | 77030 | Recruiting |
| Normunity Investigational Site | San Antonio | Texas | 78229 | Recruiting |
| Normunity Investigational Site | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07182149, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07182149 live on ClinicalTrials.gov.